Evidence map›Paper›PMID 28233640›Full record

ReviewCytotherapy2017

Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas.

Brittany C Parker Kerrigan, Yuzaburo Shimizu, Michael Andreeff, Frederick F Lang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cytotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Current status and research progress of oncolytic virus.Pharmaceutical science advances · 2024
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Brittany C Parker KerriganDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Bioengineering, Rice University, Houston, Texas, USA.
Yuzaburo ShimizuDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Neurosurgery, Juntendo University School of Medicine, Tokyo, Japan.
Michael AndreeffSection of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Frederick F LangDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Electronic address: flang@mdanderson.org.

Funding

Tropism Enhanced Oncolytic Adenovirus for the Treatment of Brain TumorsP50CA127001 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Juan Fueyo · 2008 to 2026
$41.2M
Interdisciplinary Translational Pre/Postdoctoral Program in Cancer NanotechnologyT32CA196561 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Gang Bao, Konstantin V Sokolov · 2015 to 2026
$3.0M
Bone Marrow Stem Cells: Novel Treatment of Human GliomaR01CA115729 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LANG, FREDERICK F · 2006 to 2010
$1.3M
NCI NIH HHS P50 CA127001NCI NIH HHS R01 CA115729NCI NIH HHS T32 CA196561
6 · The paper itself

Abstract

Mesenchymal stromal cells (MSCs) are a type of adult stem cell that has been exploited for the treatment of a variety of diseases, including cancer. In particular, MSCs have been studied extensively for their ability to treat glioblastoma (GBM), the most common and deadly form of brain cancer in adults. MSCs are attractive therapeutics because they can be obtained relatively easily from patients, are capable of being expanded numerically in vitro, can be easily engineered and are inherently capable of homing to tumors, making them ideal vehicles for delivering biological antitumoral agents. Oncolytic viruses are promising biological therapeutic agents that have been used in the treatment of GBMs, and MSCs are currently being explored as a means of delivering these viruses. Here we review the role of MSCs in the treatment of GBMs, focusing on the intersection of MSCs and oncolytic viruses.

Indexed as

AnimalsAntineoplastic AgentsBrain NeoplasmsCell Line, TumorGlioblastomaGliomaHumansMesenchymal Stem CellsMesenchymal Stem Cell TransplantationOncolytic VirotherapyOncolytic VirusesAntineoplastic Agentsadenovirusgliomasmesenchymal stem cellmesenchymal stromal cell

Identifiers

PMID28233640
PMCPMC5410175

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.